Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 2/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6846408 | 0.99 | MAP3K20 (0.45) | MAP3K20TAAR1MEN1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL6841217 | 0.88 | MAPT (0.41) | MAP3K20TAAR1MEN1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL6844782 | 0.84 | PTK2 (0.49) | MAP3K20TAAR1MEN1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL6846415 | 0.82 | ABL1 (0.46) | MAP3K20TAAR1MEN1MAPTKMT2A | |
| SCHEMBL6844794 | 0.76 | MAP3K20 (0.39) | MAP3K20MEN1KMT2ASCN9A | |
| SCHEMBL6844797 | 0.73 | MET (0.39) | MAP3K20MEN1KMT2A | |
| SCHEMBL7015526 | 0.72 | TAAR1 (0.45) | MAP3K20TAAR1MAPTPTK2CSF1R | |
| SCHEMBL6841246 | 0.71 | TP53 (0.47) | TAAR1MAPTCSF1R | |
| SCHEMBL6846756 | 0.71 | MTOR (0.48) | TAAR1MAPTCSF1R | |
| SCHEMBL6845411 | 0.69 | TAAR1 (0.49) | MAP3K20TAAR1MAPTBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1252146-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | MAP3K20 4/4885TAAR1 3516/4885MEN1 4396/4885 |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | MAP3K20 4/4885TAAR1 3516/4885MEN1 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.